Fischer Medical board approves unaudited financial results for Q2FY27 and half-year ended September 30
BSE India
Fischer Medical's board of directors approves the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The results include a limited review report from Bilimoria Mehta & Co, Chartered Accountants. The board meeting concluded the formal reporting of the Q2FY27 performance metrics. Specific financial figures and segmental drivers are provided in the annexed reports.
| Sep 2026 | Jun 2026 | Sep 2025 | QoQ% | YoY% | |
|---|---|---|---|---|---|
| Revenue/Sales | 107.44 | 81.92 | 86.31 | 31.15% | 24.48% |
| EBITDA | 13.52 | 12.74 | 18.74 | 6.18% | -27.82% |
| Op. profit margin(%) | 8.32 | 13.73 | 18.83 | -39.41% | -55.81% |
| Net Profit | 0.80 | 3.79 | 13.90 | -78.78% | -94.21% |
| EPS | 0.01 | 0.06 | 2.15 | -83.33% | -99.53% |
* Consolidated data
